Download Prescott`s Microbiology, 9th Edition 9 Antimicrobial Chemotherapy

Prescott’s Microbiology, 9th Edition
9
Antimicrobial Chemotherapy
CHAPTER OVERVIEW
The control or the destruction of microorganisms that reside within the bodies of humans and other animals is of
tremendous importance. This chapter introduces the principles of chemotherapy and discusses the ideal
characteristics for successful chemotherapeutic agents (including the concept of selectively damaging the target
microorganism while minimizing damage to the host). The chapter also presents characteristics of some commonly
used antibacterial, antifungal, antiviral, and antiprotozoan drugs.
LEARNING OUTCOMES
After reading this chapter you should be able to:





















trace the general history of antimicrobial chemotherapy
propose natural sources of new antimicrobial agents
explain the difference between a narrow and broad spectrum drug
correlate lack of microbial growth with selective toxicity
list common side effects of antimicrobial drugs
explain how to determine the level of antibacterial drug activity using the dilution susceptibility test, the
disk diffusion test, and the Etest®
predict antimicrobial drug levels in vivo from in vitro data
compare antibacterial drug mechanisms of action
relate side effect toxicity of antibacterial drugs to mechanism of action
explain the relative effectiveness of various antibacterial agents based on drug target
compare antifungal drug mechanisms of action
explain why there are far fewer antifungal agents than there are antibacterial agents
compare antiviral drug mechanisms of action
provide a rationale for combination drug therapy, using an anti-HIV model
explain why there are far fewer antiviral agents than there are antibacterial agents
compare the mechanisms of action of antiprotozoan drugs
relate side effects and toxicity of antiprotozoan drugs to their mechanism of action
explain why there are far fewer antiprotozoan agents than there are antibacterial agents
predict the effects (1) delivery route, (2) metabolism, and (3) local concentration on the effectiveness of an
antimicrobial drug
correlate the sensitivity of a microorganism to an antimicrobial agent with microbial growth in the presence of
that agent
identify practices that lead to antimicrobial drug resistance and suggest countermeasures
CHAPTER OUTLINE
I.
The Development of Chemotherapy
A. Paul Ehrlich (1904–1909)—aniline dyes and arsenic compounds
B. Gerhard Domagk, and Jacques and Therese Trefouel (1939)—sulfanilamide
C. Ernest Duchesne (1896) discovered penicillin, however, this discovery was not followed up
D. Alexander Fleming (1928) accidentally discovered the antimicrobial activity of penicillin on a
contaminated plate; however, follow-up studies did not show the drug would remain active in the body
long enough to be effective
1
© 2014 by McGraw-Hill Education. This is proprietary material solely for authorized instructor use. Not authorized for sale or distribution in any
manner. This document may not be copied, scanned, duplicated, forwarded, distributed, or posted on a website, in whole or part. 
Prescott’s Microbiology, 9th Edition
E.
Howard Florey and Ernst Chain (1939) aided by the biochemist, Norman Heatley, worked from Fleming’s
published observations, obtained a culture from him, and demonstrated the effectiveness of penicillin
F. Selman Waksman (1944)—streptomycin; this success led to a worldwide search for additional antibiotics,
and the field has progressed rapidly since then
II. General Characteristics of Antimicrobial Drugs
A. Selective toxicity—ability to kill or inhibit microbial pathogen with minimal side effects in the host
1. Therapeutic dose—the drug level required for clinical treatment of a particular infection
2. Toxic dose—the drug level at which the agent becomes too toxic for the host (produces undesirable
side effects)
3. Therapeutic index—the ratio of toxic dose to therapeutic dose: the larger the better
B. Chemotherapeutic agents can occur naturally, be synthetic, or semisynthetic (chemical modifications of
naturally occurring antibiotics)
C. Drugs with narrow-spectrum activity are effective against a limited variety of pathogens; drugs with
broad-spectrum activity are effective against a wide variety of pathogens
D. Drug can be cidal (able to kill) or static (able to reversibly inhibit growth)
E. Minimal inhibitory concentration (MIC) is the lowest concentration of the drug that prevents growth of a
pathogen; minimal lethal concentration (MLC) is the lowest drug concentration that kills the pathogen
III. Determining the Level of Antimicrobial Activity
A. Dilution susceptibility tests—a set of broth-containing tubes are prepared; each tube in the set has a
specific antibiotic concentration; to each is added a standard number of test organisms
1. The lowest concentration of the antibiotic resulting in no microbial growth is the MIC
2. Tubes showing no growth are subcultured into tubes of fresh medium lacking the antibiotic to
determine the lowest concentration of the drug from which the organism does not recover; this is the
MLC
B. Disk diffusion tests
1. Disks impregnated with specific drugs are placed on agar plates inoculated with the test organism;
clear zones (no growth) will be observed if the organism is sensitive to the drug; the size of the clear
zone is used to determine the relative sensitivity; zone width also is a function of initial
concentration, solubility, and diffusion rate of the antibiotic
2. Kirby-Bauer method is most commonly used disk diffusion test; test results are determined using
tables that relate zone diameter to the degree of sensitivity
C. The Etest®
1. Especially useful for testing anaerobic microorganisms
2. Makes use of special plastic strips that contain a concentration gradient of an antibiotic; each strip is
labeled with a scale of MIC values; after incubation an elliptical zone of inhibition is observed and
its intersection with the strip is used to determine the MIC
IV. Antibacterial Drugs
A. Inhibitors of cell wall synthesis are effective and selective because bacterial cell walls have unique
structures not found in eukaryotic cells
1. Penicillins—inhibit cell wall synthesis; many types have been identified or synthesized including
ampicillin, carbenicillin, and methicillin; they differ in spectrum of activity and administration route
but all have a -lactam ring that is crucial for activity; resistance is an increasing problem, often due
to penicillinase; some patients are allergic to these antibiotics
2. Cephalosporins—inhibit cell wall synthesis; broad spectrum of activity; they contain a -lactam ring,
but are not subject to degradation by penicillinase; they can be given to some patients with penicillin
allergies; they include cephalothin, cefoxitin, and ceftriazone
3. Vancomycin and teicoplanin—glycopeptide antibiotics that block peptidoglycan synthesis;
vancomycin is particularly important as the last line of defense against antibiotic-resistant
staphylococcal and enterococcal infections
B. Protein synthesis inhibitors exploit the differences between prokaryotic and eukaryotic ribosomes
1. Aminoglycosides—contain cyclohexane ring and amino sugars; includes kanamycin, streptomycin,
neomycin, and gentamicin; can be quite toxic to patients; act through interference with 30S
ribosomal subunit, causing mistranslation with damaged proteins activating the envelope stress
response and oxidative damage
2
© 2014 by McGraw-Hill Education. This is proprietary material solely for authorized instructor use. Not authorized for sale or distribution in any
manner. This document may not be copied, scanned, duplicated, forwarded, distributed, or posted on a website, in whole or part. 
Prescott’s Microbiology, 9th Edition
2.
Tetracyclines—contain a four-ring structure with side chains; very broad spectrum that includes
intracellular parasites and mycoplasmas; bacteriostatic
3. Macrolides—12- to 22-carbon lactone rings linked to sugars; broad spectrum similar to that of
penicillin; includes erythromycin and clindamycin; inhibit peptide chain elongation by binding
rRNA
4. Chloramphenicol—has a broad spectrum but is quite toxic; inhibits peptidyl transfer reaction
C. Metabolic antagonists are structural analogs of metabolic intermediates that act as antimetabolites,
inhibiting metabolic pathways; bacteriostatic
1. Sulfonamides or sulfa drugs—inhibit folic acid synthesis in bacteria (humans don’t synthesize folic
acid, so are not affected); resistance is increasing and many patients are allergic to these drugs;
includes p-aminobenzoic acid (PABA)
2. Trimethoprim—synthetic antibiotic that blocks folic acid production; broad spectrum often
combined with sulfa drugs
D. Nucleic acid synthesis inhibitors block enzymes of transcription and translation; generally not as
selectively toxic
1. Quinolones—synthetic drugs that inhibit bacterial DNA gyrase or topoisomerase II, thereby
disrupting replication, repair, and other processes involving DNA; broad spectrum; includes
nalidixic acid and ciprofloxacin (Cipro)
V. Antifungal Drugs
A. Fungal infections are more difficult to treat than bacterial infections because the greater similarity of fungi
and host limits the ability of a drug to have a selective point of attack; furthermore, many fungi have
detoxification systems that inactivate drugs
B. Superficial mycoses are infections of superficial tissues and can often be treated by topical application of
antifungal drugs such as miconazole, nystatin, and griseofulvin, thereby minimizing systemic side effects
C. Systemic mycoses are more difficult to treat and can be fatal; amphotericin B and flucytosine have been
used with limited success; amphotericin B is highly toxic and must be used with care; flucytosine must be
converted by the fungus to an active form, and animal cells are incapable of this; some selectivity is
possible, but severe side effects have been observed with both drugs; posaconazole is effective against
drug-resistant fungi and are less toxic
D. Subcutaneous mycoses (e.g., mycetomas) are treated with a mixture of therapies
VI. Antiviral Drugs
A. Selectivity is a problem because viruses use the metabolic machinery of the host
B. Antiviral drugs target specific steps of life cycle, including viral uncoating and DNA replication (e.g.,
amantadine, vidarabine, acyclovir, cidofovir, and azidothymidine)
C. Anti-HIV drugs (e.g., AZT, ddI, 3TC) have four targets: nucleoside reverse transcriptase inhibitors
(NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (block viral
polypeptide processing), and fusion inhibitors (block viral entry into cell); combinations of drugs often
used
D. Tamiflu is a neuraminidase inhibitor that is used to treat influenza
VII. Antiprotozoan drugs
A. Mechanisms of action for antiprotozoan drugs are largely unknown; as protozoans and humans are both
eukaryotes, selective toxicity is difficult to achieve
B. Chloroquine and mefloquine—used to treat malaria; variety of mechanisms proposed
C. Artemisinin—anti-malarial drug used in traditional Chinese medicine
D. Metronidazole—used to treat Entamoeba infections; appears to interact with DNA
E. Atovaquone—an analog of ubiquinone that interferes with electron transport chain
VIII. Factors Influencing the Antimicrobial Drug Effectiveness
A. Drug effectiveness—this is greatly influenced by the mode of administration (e.g., oral, topical,
parenteral), but also can be influenced by exclusion from the site of infections (e.g., blood clots or
necrotic tissue protects bacterium)
B. Susceptibility of pathogen—influenced by growth rate and by inherent properties (e.g., whether or not
pathogen has target of the drug)
3
© 2014 by McGraw-Hill Education. This is proprietary material solely for authorized instructor use. Not authorized for sale or distribution in any
manner. This document may not be copied, scanned, duplicated, forwarded, distributed, or posted on a website, in whole or part. 
Prescott’s Microbiology, 9th Edition
C.
D.
Factors influencing drug concentration in the body—must exceed the pathogen’s MIC for the drug to be
effective; this will depend on the amount of drug administered, the route of administration, the speed of
uptake, and the rate of clearance (elimination) from the body
Overcoming drug resistance
1. Several strategies can be used to discourage emergence of drug resistance (e.g., administration of
high doses, simultaneous treatment with more than one drug, limited use of broad-spectrum
antibiotics)
2. Drug resistance has become an increasing problem; new drugs are constantly being developed and
new treatment methods (e.g., phage treatment of bacterial infections) are being explored
CRITICAL THINKING
1.
Antibiotics are natural products of certain microorganisms. What advantages might these antibiotics provide for
the organisms that produce them?
2.
Viruses generally use the metabolic machinery of their hosts. Therefore, they should present no selective
point of attack for potential antiviral drugs. Yet, recently there have been several antiviral drugs
developed that have a reasonably high therapeutic index. Explain.
3. Chemotherapeutic agents that are variations of natural biotic products dominate the lists of antimicrobials.
Many of these agents specifically target one particular biochemical process. In this way, they provide a
strong selective pressure directed at a narrow target. Comment on how this may lead to natural selection
of organisms that achieve mutations in particular pathways that facilitate resistance to chemotherapeutic
substances.
CONCEPT MAPPING CHALLENGE
Construct a concept map based on table 9.1 that highlights some of the common antibiotics taking into account their
mechanism of action. Be sure to include: cell wall disruption, membrane permeability, protein synthesis inhibitors,
DNA replication disruptors, and metabolic disruptors.
4
© 2014 by McGraw-Hill Education. This is proprietary material solely for authorized instructor use. Not authorized for sale or distribution in any
manner. This document may not be copied, scanned, duplicated, forwarded, distributed, or posted on a website, in whole or part. 